Skip to main
  1. Stocks
  2. Sionna Therapeutics Inc
  3. Forecast
SION

SION Stock Forecast & Price Target

SION Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 22%
Hold 22%
Sell 11%
Strong Sell 0%

Bulls say

Sionna Therapeutics is viewed positively because its cystic fibrosis platform targets CFTR dysfunction through a differentiated NBD1 stabilizer strategy, which could address the disease’s underlying biology rather than only symptoms. The cited 14-day study showed that excluding outliers improved the observed sweat chloride change from -1.0 to -3.8 mmol/L, with the secondary analysis reaching -8.6 mmol/L, suggesting meaningful pharmacodynamic activity despite unusual non-adherence in a small trial. Management also believes the SION-451/SION-2222 regimen should avoid the drug-drug interaction concerns seen with SION-719 and Trikafta, strengthening confidence in the company’s lead combination approach.

Bears say

Sionna Therapeutics is viewed negatively because its Phase 2a PreciSION study failed to validate the company’s CFHBE platform, with SION-719 missing the primary sweat chloride endpoint at -1.0 mmol/L versus a >10 mmol/L goal and management discontinuing further development. The study’s interpretation was clouded by lower-than-expected Trikafta exposures, non-adherence concerns, and possible assay confounding, which raises fundamental doubts about whether its translational model can reliably predict meaningful clinical benefit in CF patients. With SION-451 still needing time to advance and safety/tolerability questions plus financing risk persisting, the stock appears range bound while the company relies on cash projected at about $4/share in 3Q26 and runway into 4Q28.

SION has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 22% recommend Buy, 22% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sionna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

SION Analyst Forecast & Price Prediction

Get the latest SION stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in SION

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sionna Therapeutics Inc (SION) Forecast

Analysts have given SION a Buy based on their latest research and market trends.

According to 9 analysts, SION has a Buy consensus rating as of Nov 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sionna Therapeutics Inc (SION)


SION Analyst Forecast & Price Prediction

Get the latest SION stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in SION

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover SION stock data and trends